配种到户几种保定方法

随着科学技术的不断创新,通讯事业飞速发展,千家万户都安上了电话,家畜繁育改良工作也由过去在繁育中心坐家配种转变为主动到农户家中服务,母畜保定就成了当前比较棘手的问题.为了解决母畜保定问题,我们采用了以下几种方法仅供参考.     

黑龙江省养蜂史概况(二)

二十世纪前半期一、意大利蜂的引入1903￣1920年,西方蜂种(主要是意蜂)及新养蜂法先传入福建、广东、香港、天津、北京等地,不久也传入黑龙江省。民国初年的养蜂情况《珠河县志》有以下记载:"民国初年,西洋蜂种及养蜂法传来以后,     

母猪产后不食的分型疗法

(一)病因类型 1.消化不良型:母猪产前精料喂的过多,或突然更换饲料,加重胃肠负担,引起消化不良.此病常发于分娩之后,体温正常,食欲不振,粪便先干后稀,有的病猪喜欢喝点成汤,有的吃点鲜块茎和生米等食物,但数量不大,严重者食欲废绝.     

国内玉米价格涨跌两难

随着年关临近，为了确保产区农民收入稳定增长，近日，政府有关部门出台了东北储备粮收购计划。在该重大利好政策拉动之下，我国部分产区玉米价格有望触底反弹，但受市场供应依然充足、需求整体依旧偏弱影响，国内玉米市场行情涨跌两难，具体分析如下：     

美利奴羊胃穿孔并发膀胱结石误诊为吞食异物一例

2005年6月联合国粮农组织在南太平洋热带雨林地区汤加王国推广饲养肉用美利奴绵羊,耗资14万美元(种公羊5 000美元/只,种母羊3 000美元/只)从斐济引进成年种公羊4只、成年种母羊40只,投放在汤加王国主岛——汤加塔布岛宛立(Vaili Tongatapu)国营农场进行适应性观察,发病种羊是其中的一只种公羊。     

省级兽药经销商经营模式分析

这里所说的省级兽药经销商并不是一个确切的概念,而是泛指在省内跨地区经营的较大规模的兽药经销商,一般分布在地区级城市或养殖业发达的县城、乡镇。在吉林省内数量不多,但其影响很大,对市场起主导作用,代表着兽药市场的现状及今后的发展方向,研究他们的经营模式及每一种模     

警犬百日连破11起千克大案

2007年4月3日晚,云南公安边防总队德宏边防支队江桥警犬复训基地执勤官兵在公开查缉过程中,使用警犬"辉杰"对车体实施搜嗅,当场从空调内查获用黄色胶带包裹的毒品海洛因一坨,净重1410克。这是该基地今年以来使用警犬破获的第11起千克贩毒大案。     

主要组培花卉品种介绍

非洲菊:又名扶朗花,菊科,大丁草属,多年生草本植物;原产非洲南部,性喜温暖,阳光充足和空气流通的环境,不耐寒,忌炎热,生长适温20￣25℃,喜疏松、肥沃、排水良好且富含有机质的微酸性土壤。园艺品种花色丰富,有白、红、粉、黄等色系。兼有切花和盆花类型。彩色马蹄莲:天南星科多     

对河南桑蚕“十一·五”发展规划的几点建议

<正>河南省地处黄河中下游，蚕业生产历史悠久。建国50年以来，尤其是近20g间，经过“七·五”至“八·五”的迅速发展和“九·五”、“十·五”的稳步调整，河南蚕业生产规模基本稳定，生产水平得到提高。目前全省桑园面积1．67万hm~2，年产桑蚕茧6000t，与建国时相比，桑园面积和蚕茧产量分别增长了24倍和42．2倍，与改革开放初期的1978年相比，分别增长了2．25倍和4．18倍；蚕业深加工等综合产值达到10亿元，农民收入达5亿元，出口创汇8600多万美元。“九·五”、“十·五”期间，河南茧丝绸业保持着北方诸省(山东、陕西省除外)生产、出口主要基地和传统优势产业、出口创汇大户的地位。蚕业生产已成为不少平原和山区农民脱贫致富奔小康的支柱产业。 1 “九·五”、“十·五”实际生产情况 1．1 实际生产情况 1．1．1 生产规模保持基本稳定桑蚕生产在经历了1995年“全面下滑”桑园规模大幅度缩减后，“九·五”期间，全省蚕茧的总产和年产量也相应减少，但集中产     

缩小分组饲养的面积

在丹麦,人们已经提出一个分组饲养妊娠母猪的新观念,名叫"最佳猪栏",它把群饲设备与单独饲喂和铺有稻草、排水良好的地面结合在一起,见图1.对这种设计的研究显示,给妊娠母猪建成一个既有饲喂/休息的去处,又有一个铺垫良好的躺卧处的猪栏-所占面积总量与配备给群饲母猪的电子饲喂系统的场地所使用的面积相当.     

新型兽用纳米乳载药系统在大鼠体内的药代动力学研究

为了解氟苯尼考纳米乳(FFNE)在大鼠体内药代动力学行为,本试验以氟苯尼考溶液(FFSol)为参比制剂,以30 mg/kg剂量给大鼠灌胃和肌内注射给药,分别于给药后0.5、1、2、4、8、12、24、36、48、72 h采血,利用高效液相色谱法测定血浆中氟苯尼考含量,利用DAS 2.0软件计算房室模型与非房室模型条件下药代动力学参数。结果显示,在两种给药方式下,FFNE与FFSol在大鼠体内均符合二室模型。灌胃给药后,FFNE与FFSol在房室模型条件下AUC_(0-∞)分别为1 085.047和2 176.490 mg/L·h,半衰期分别为10.566和13.687 h,FFNE的相对生物利用度为187.4%。肌内注射给药后,FFNE与FFSol在房室模型条件下AUC_(0-∞)分别为1 530.55和3 243.338 mg/L·h,半衰期分别为7.533和13.335 h,FFNE的相对生物利用度为211.9%。结果表明,FFNE通过灌胃和肌内注射给药在大鼠体内分布较广,灌胃相对肌内注射吸收差,消除快。将氟苯尼考制成纳米乳剂后促进了氟苯尼考的吸收,氟苯尼考的生物利用度显著提高。     

Pharmacokinetics of ofloxacin in broiler chicken

Pharmacokinetics of ofloxacin, a fluoroquinolone antimicrobial agent, was determined in broiler chickens after intravenous or oral administration of a single dose (10 mg/kg). Ofloxacin concentrations in plasma were determined using a high-performance liquid chromatography assay. Plasma concentration profiles were analyzed by the noncompartmental method. Elimination half-life and mean residence time of ofloxacin in plasma were 4.46 and 5.48 h after intravenous administration and 5.85 and 7.43 h, respectively, after oral administration. Maximal plasma concentration of 3.65 microg/mL was achieved at 1.25 h after oral administration. Apparent volume of distribution of 1.76 and 2.16 L/kg and total body clearance of 4.96 and 4.5 mL/min/kg were obtained following intravenous and oral administration, respectively. The oral bioavailability of ofloxacin was 110.01%. Ofloxacin was found to be more rapidly absorbed, widely distributed and more quickly eliminated than other fluoroquinolones in broilers. Based on these kinetic parameters, a dosage of 10 mg/kg given orally every 24 h can be recommended for the treatment of bacterial infections with MIC90 < 0.3 microg/mL.     

Pharmacokinetics of amoxicillin trihydrate in cultured olive flounder (Paralichthys olivaceus)

The study was aimed at investigating the pharmacokinetics of amoxicillin trihydrate (AMOX) in olive flounder (Paralichthys olivaceus) following oral, intramuscular, and intravenous administration, using high‐performance liquid chromatography following. The maximum plasma concentration (C_max), following oral administration of 40 and 80 mg/kg body weight (b.w.), AMOX was 1.14 (T_max, 1.7 h) and 0.76 μg/mL (T_max, 1.6 h), respectively. Intramuscular administration of 30 and 60 mg/kg of AMOX resulted in C_max values of 4 and 4.3 μg/mL, respectively, with the corresponding T_max values of 29 and 38 h. Intravenous administration of 6 mg/kg AMOX resulted in a C_max of 9 μg/mL 2 h after administration. Following oral administration of 40 and 80 mg/kg AMOX, area under the curve (AUC) values were 52.257 and 41.219 μg/mL·h, respectively. Intramuscular 30 and 60 mg/kg doses resulted in AUC values of 370.274 and 453.655 μg/mL·h, respectively, while the AUC following intravenous administration was 86.274 μg/mL·h. AMOX bioavailability was calculated to be 9% and 3.6% following oral administration of 40 and 80 mg/kg, respectively, and the corresponding values following intramuscular administration were 86% and 53%. In conclusion, this study demonstrated high bioavailability of AMOX following oral administration in olive flounder.     

Comparison of plasma pharmacokinetics and bioavailability of ceftiofur sodium and ceftiofur hydrochloride in pigs after a single intramuscular injection

Ceftiofur sodium, a broad-spectrum cephalosporin, is active against gram-positive and gram-negative pathogens of veterinary importance. Two studies were designed to compare the intramuscular bioavailability of the current sodium salt and the new hydrochloride salt in pigs at doses of either 3 mg or 5 mg ceftiofur equivalents (CE)/kg body weight. Twenty-six healthy young pigs were selected for these two-period, two-treatment crossover studies, 12 for the 3 mg/kg study and 14 for the 5 mg/kg study. Each animal received one intramuscular (i.m.) injection of ceftiofur sodium and one i.m. injection of ceftiofur hydrochloride with a 14-day washout period between the two treatments. Blood samples were collected serially for up to 96 h postinjection. Plasma samples were then analysed using a validated assay that measures ceftiofur and all desfuroylceftiofur-related metabolites by high-performance liquid chromatography. In the 3 mg/kg dosage study, average maximum plasma concentration (C(max)) after administration of ceftiofur sodium was 15.8+/-3.40 microg/mL at 0.4-4 h after injection. After administration of ceftiofur hydrochloride, the C(max) was 11.8+/-1.67 microg/mL at 1-4 h after injection. Concentrations of ceftiofur and metabolites 72 h after the injection were 0.392+/-0.162 microg/mL for ceftiofur hydrochloride and 0.270+/-0.118 microg/mL for ceftiofur sodium. The mean area under the curve (AUC), from time 0 to the limit of quantitation (AUC(O-LOQ)) after ceftiofur hydrochloride administration, was 216+/-28.0 microg x h/mL, compared to 169+/-45.4 microg x h/mL after ceftiofur sodium administration. The calculated time during which plasma concentrations remained above 0.02 microg/mL (t(>0.2)) was 85.3+/-10.6 h for ceftiofur sodium and 77.2+/-10.7 h for ceftiofur hydrochloride. In the 5 mg/kg dosage study, C(max) after administration of ceftiofur sodium was 28.3+/-4.45 microg/mL at 0.33-2 h after injection. After administration of ceftiofur hydrochloride, the C(max) was 29.7+/-6.72 microg/mL at 0.66-2 h after injection. Concentrations of ceftiofur and metabolites 96 h after the injection were 0.274+/-0.0550 microg/mL for ceftiofur hydrochloride and 0.224+/-0.0350 microg/mL for ceftiofur sodium. The mean AUC(O-LOQ) after ceftiofur hydrochloride administration was 382+/-89.8 microg x h/mL compared to 302+/-54.4 microg x h/mL after ceftiofur sodium administration. The t(>0.2) was 78.9+/-9.65 h for ceftiofur sodium and 94.2+/-8.64 h for ceftiofur hydrochloride. Based on the similarity of the pharmacokinetic parameters of the sodium and hydrochloride formulations of ceftiofur, similar therapeutic efficacy can be inferred for the two products.     

Pharmacokinetics of valnemulin after intravenous,intramuscular, and oral administration in layer chickens

The pharmacokinetic characteristics of valnemulin in layer chickens were studied after single intravenous, intramuscular, and oral administration at a dose of 15 mg/kg body weight. Plasma samples at certain time points were collected and the drug concentrations in them by ultra high‐performance liquid chromatography tandem mass spectrometry (UHPLC‐MS). The concentration–time data for each individual were plotted by noncompartmental analysis for the whole three routes. Following intravenous administration, the plasma concentration showed tiny fluctuation. The elimination half‐life (), total body clearance (Cl), and area under the plasma concentration–time curve (AUC) were 1.85 ± 0.43 h, 2.2 ± 0.9 L/h, and 7.52 ± 2.46 μg·h/mL, respectively. Following intramuscular administration, the peak concentration (C_max, 1.40 ± 0.43 μg/mL) was achieved at the time of 0.34 h. A multiple‐peak phenomenon existed after oral administration, and the first peak and secondary peak were at 10 min and during 2–4 h, respectively, while the tertiary peak appeared during 5–15 h. The bioavailability (F %) for intramuscular and oral administration was 68.60% and 52.64%, respectively. In present study, the detailed pharmacokinetic profiles showed that this drug is widely distributed and rapidly eliminated, however has a low bioavailability, indicating that valnemulin is likely to be a favorable choice in the clinical practice.     

Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs

Bimazubute, M., Cambier, C., Baert, K., Vanbelle, S., Chiap, P., Gustin, P. Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs. J. vet. Pharmacol. Therap. 34 , 176–183. The penetration of oxytetracycline (OTC) in plasma and nasal secretions of healthy pigs was evaluated during the first study, in response to oral dose of 20 mg of OTC per kg of body weight (bwt) per day as a 400 mg/kg feed medication (n = 5) and to intramuscular (i.m.)‐administered formulations at 10 mg/kg bwt (n = 5), 20 mg/kg bwt (n = 5), 40 mg/kg bwt (n = 5). Concentrations of OTC in plasma and nasal secretions were determined by a validated ultra‐high performance liquid chromatography associated to tandem mass spectrometry method (UPLC/MS/MS). The objectives were to select the efficacy treatment and to evaluate the possibility to predict nasal secretions concentrations from those determined in plasma. The animals were housed together in each experiment. In each group, the treatment was administered once daily during 6 consecutive days, and nasal secretions and plasma were collected after 4 and 24 h at day 2 and day 6. For oral administration, only one medicated feed was prepared and distributed to all the animals together and was consumed in approximately 1 h. To meet recommendations of efficacy for OTC in nasal secretions, only the i.m. of 40 mg/kg bwt associated to an inter‐dosing interval of 24 h provides and maintains concentrations in nasal secretions ≥1 μg/mL, appropriate to the MIC 50 and 90 of Pasteurella multocida and Bordetella bronchiseptica, respectively, the main pathological strains in nasal secretions. It has been demonstrated that, using a generalized linear mixed model (GLMM), OTC in the nasal secretions (μg/mL) can be predicted taking into account the OTC concentrations in plasma (μg/mL), according to the following equation: OTC_{nasal secretions} = 0.28 OTC_plasma?1.49. In a second study, the pharmacokinetic behaviour of OTC in plasma and nasal secretions of healthy pigs was investigated, after single‐dose i.m. of 40 mg/kg bwt of the drug. Blood samples and nasal secretions were collected at predetermined times after drug administration. The data collected in 10 pigs for OTC were subjected to non‐compartmental analysis. In plasma, the maximum concentration of drug (C_max), the time at which this maximum concentration of drug (T_max) was reached, the elimination half‐life (t½) and the area under the concentration vs. time curve (AUC) were, respectively, 19.4 μg/mL, 4.0, 5.1 h and 150 μg·h/mL. In nasal secretions, C_max, T_max, t½ and AUC were, respectively, 6.29 μg/mL, 4.0, 6.6 h and 51.1 μg·h/mL.     

喹烯酮在鸡体内的代谢及药物动力学研究

以HPLC-MS/MS为定量手段,研究了喹烯酮经静脉注射(2.5 mg/kg)、口服(30 mg/kg)两种给药途径在鸡体内的代谢及药物动力学特征.鸡静脉注射喹烯酮后,血浆中检测到喹烯酮原药和1-脱氧喹烯酮;口服灌注喹烯酮后,血浆中检测到喹烯酮原药和3-甲基喹噁啉-2-羧酸(MQCA).喹烯酮在鸡体内的药动学数据采用统...     

Pharmacokinetics of florfenicol and its metabolite,florfenicol amine,in rice field eel (Monopterus albus) after a single‐dose intramuscular or oral administration

The pharmacokinetics of florfenicol (FF) and its metabolite, florfenicol amine (FFA), were studied in rice field eel (Monopterus albus) after a single dose (20 mg/kg) by intramuscular (i.m.) or oral gavage (p.o.) dose at 25 °C. The elimination half‐lives (t_1/2β), peak concentration of FF (C_max), and time to reach FF peak concentration (T_max) in plasma were estimated as 18.39 h, 10.83 μg/mL, and 7.00 h, respectively, after i.m. injection and 13.46 h, 8.37 μg/mL, and 5 h, respectively, after p.o. administration. The T_max values of FF in tissues (i.e., kidney, muscle, and liver) were larger for i.m. injection compared with those for p.o. administration. The t_1/2β had the following order kidney > muscle > liver for i.m. administrated and kidney > liver > muscle for p.o. administrated. The largest area under the concentration–time curve (AUC) was calculated to be 384.29 mg · h/kg after i.m. dosing, and the mean residence time (MRT) was 42.46 h by oral administration in kidney. FFA was also found in all tissues with a lower concentration than FF for both i.m. and p.o. administrations throughout the study. The elimination of FFA was slow with a t_1/2β between 18.19 and 47.80 h in plasma and tissues. The mean metabolic rate of FFA for i.m. and p.o. administrations was >23.30%.     

Pharmacokinetics of florfenicol in crucian carp (Carassius auratus cuvieri) after a single intramuscular or oral administration

The pharmacokinetics of florfenicol (FF) was studied in plasma after a single dose (40 mg/kg) of intramuscular (i.m.) or oral gavage (p.o.) administration to crucian carp (Carassius auratus cuvieri) in freshwater at 25 °C. Ten fish per sampling point were examined after treatment. The data were fitted to two-compartment open models follow both routes of administration. The estimates of total body clearance (CL(b) ), volume of distribution (V(d) /F), and absorption half-life (T(1/2(ka)) ) were 0.067 L/h/kg and 0.145 L/h/kg, 2.21 L/kg and 1.04 L/kg, 2.75 and 1.54/h following i.m. and p.o. administration, respectively. After i.m. injection, the elimination half-life (T(1/2(β)) ) was calculated to be 38.2h, the maximum plasma concentration (C(max) ) to be 16.82 μg/mL, the time to peak plasma FF concentration (T(max) ) to be 1.50 h, and the area under the plasma concentration-time curve (AUC) to be 597.4 μg/mL·h. Following p.o. administration, the corresponding estimates were 2.17 h, 29.32 μg/mL, 1.61 h, and 276.1 μg/mL·h.     

Plasma chloramphenicol concentrations in cats after parenteral administration of chloramphenicol sodium succinate

Five cats were dosed on five occasions with 20 mg chloramphenicol/kg body weight. The drug was given three times as chloramphenicol sodium succinate (by intravenous, intramuscular and subcutaneous injections) and twice as crystalline chloramphenicol in capsules. Plasma chloramphenicol concentrations were determined at fixed intervals after administration. Parenteral injection of the ester usually produced highest plasma levels at the initial sampling, 0.5 h after dosing. When capsules were given, there was greater variation between cats: highest plasma levels were recorded usually at 0.5-2 h after dosage but delayed absorption was evident in some cases. There were no statistically significant differences between the different routes with regard to mean plasma antibiotic levels at each sampling or mean area under the curve of plasma level versus time, except that mean plasma levels at 0.5 h were higher with intravenous or intramuscular injection than with oral administration.